Intervention
Marine EPA/DHA supplements
Research Observatory
Evidence Update
Current evidence
Marine eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) supplements were compared with placebo in VITAL primary prevention and with corn-oil control in STRENGTH high-risk statin-treated adults. VITAL's marine omega-3 supplement did not significantly reduce its primary major cardiovascular endpoint in general primary prevention. REDUCE-IT's cardiovascular benefit and STRENGTH's null result cannot be collapsed into a class-wide fish-oil claim.
In VITAL Rhythm, the tested marine omega-3 supplement did not significantly prevent atrial fibrillation, an irregular heart rhythm, compared with placebo in adults without that condition at entry. The uncertainty still allows modest benefit or harm. This finding does not establish effects for every omega-3 product or for higher-dose formulations. Population: 25119 adults without baseline cardiovascular disease, cancer or atrial fibrillation; mean 66.7, 50.8% women. Species: Homo sapiens Intervention and comparator: Marine omega-3 fatty acids, 1 g/day capsule containing EPA 460 mg and DHA 380 mg Comparator: Matching omega-3 placebo within the VITAL factorial design Endpoint: Incident atrial fibrillation; omega-3 factorial contrast Reported result: 469 versus 431 events; HR 1.09 (0.96–1.24), P=0.19. Follow-up: Median 5.3 years
What changed
VITAL and STRENGTH primary cardiovascular comparisons were null; this does not negate REDUCE-IT for a distinct prescription EPA formulation.VITAL Rhythm did not demonstrate atrial-fibrillation prevention with its marine omega-3 formulation.
What did not change
Cross-trial differences cannot identify whether formulation, comparator or risk caused the different results.CI permits modest benefit or harm; no extrapolation to high-dose purified EPA or all omega-3 products.
Why it matters
Prevents fish-oil class claims and preserves formulation-specific adverse tradeoffs.
Main limitation
Secondary MI finding does not reverse primary result; not equivalent to high-dose prescription EPA or proof of no effect. No head-to-head randomization; formulation, comparator and risk differ. Serious bleeding in REDUCE-IT 2.7% vs 2.1%, p=.06, is not confirmed absence of risk.CI permits modest benefit or harm; no extrapolation to high-dose purified EPA or all omega-3 products. Design: Randomized 2x2 factorial ancillary trial Safety: AF is itself a clinically relevant adverse outcome; these doses do not settle high-dose formulation safety. Interpretation: Factorial contrasts can coincidentally have identical event counts.
Next proof
A direct randomized comparison of specified formulations and comparators in the same risk population, with prespecified cardiovascular and safety outcomes.Formulation- and dose-specific AF evidence.
Summary
Marine eicosapentaenoic acid/docosahexaenoic acid (EPA/DHA) supplements were compared with placebo in VITAL primary prevention and with corn-oil control in STRENGTH high-risk statin-treated adults. VITAL's marine omega-3 supplement did not significantly reduce its primary major cardiovascular endpoint in general primary prevention. REDUCE-IT's cardiovascular benefit and STRENGTH's null result cannot be collapsed into a class-wide fish-oil claim.
Intelligence Take
Prevents fish-oil class claims and preserves formulation-specific adverse tradeoffs.
Limitations
Secondary MI finding does not reverse primary result; not equivalent to high-dose prescription EPA or proof of no effect. No head-to-head randomization; formulation, comparator and risk differ. Serious bleeding in REDUCE-IT 2.7% vs 2.1%, p=.06, is not confirmed absence of risk.